These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 18849606

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles.
    Ettefagh L, Nedorost S, Mirmirani P.
    Arch Dermatol; 2004 Aug; 140(8):1012. PubMed ID: 15313825
    [No Abstract] [Full Text] [Related]

  • 6. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
    Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G.
    Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Alopecia areata during anti-TNF alpha therapy: Nine cases].
    Le Bidre E, Chaby G, Martin L, Perrussel M, Sassolas B, Sigal ML, Kaassis C, Lespessailles E, Nseir A, Estève E.
    Ann Dermatol Venereol; 2011 Jun; 138(4):285-93. PubMed ID: 21497255
    [Abstract] [Full Text] [Related]

  • 11. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T, Minota S.
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians.
    Arthritis Rheum; 2009 May 15; 61(5):560-8. PubMed ID: 19405000
    [Abstract] [Full Text] [Related]

  • 15. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH, Glass R, Cui J, Shadick N.
    JAMA; 2006 Nov 08; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract] [Full Text] [Related]

  • 16. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE, Schaible TF, Boscia JA.
    JAMA; 2006 Nov 08; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract] [Full Text] [Related]

  • 17. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D, Wolff B.
    JAMA; 2006 Nov 08; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, Pontikaki I.
    Arthritis Rheum; 2004 Apr 15; 51(2):301-2. PubMed ID: 15077278
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.